NASDAQ:CDXCChromadex Stock Price, Forecast & News

Chromadex's stock was trading at $3.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CDXC shares have increased by 38.6% and is now trading at $5.10.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chromadex.

Chromadex is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Chromadex.

Chromadex will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chromadex Corp (NASDAQ:CDXC) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. The business had revenue of $14.35 million for the quarter, compared to analyst estimates of $13.76 million. Chromadex had a negative net margin of 58.73% and a negative return on equity of 132.48%.
View Chromadex's earnings history.

3 equities research analysts have issued twelve-month price targets for Chromadex's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Chromadex's stock price to reach $6.33 in the next year. This suggests a possible upside of 24.2% from the stock's current price.
View analysts' price targets for Chromadex.

Media stories about CDXC stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chromadex earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
View the latest news about Chromadex.

Chromadex saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 2,410,000 shares, an increase of 7.1% from the June 30th total of 2,250,000 shares. Based on an average daily volume of 463,500 shares, the short-interest ratio is currently 5.2 days. Currently, 6.6% of the company's stock are sold short.
View Chromadex's Current Options Chain.

Some companies that are related to Chromadex include Aurora Cannabis (ACB), Tilray (TLRY), Canopy Rivers (RIV), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU), Tauriga Sciences (TAUG), GLG Life Tech (GLGLF), Nutra Pharma (NPHC) and Beleave (BE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Heron Therapeutics (HRTX), Tilray (TLRY), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

Chromadex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sycale Advisors NY LLC (0.59%), UBS Group AG (0.33%), Raymond James Financial Services Advisors Inc. (0.14%), Insight 2811 Inc. (0.05%) and SG Americas Securities LLC (0.04%). Company insiders that own Chromadex stock include Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for Chromadex.

CDXC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Chromadex.

CDXC stock was bought by a variety of institutional investors in the last quarter, including Sycale Advisors NY LLC, SG Americas Securities LLC, and Insight 2811 Inc.. Company insiders that have bought Chromadex stock in the last two years include Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for Chromadex.

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXC stock can currently be purchased for approximately $5.10.

Chromadex has a market capitalization of $313.55 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe.

The official website for Chromadex is www.chromadex.com.

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]